Companies › ABOS

ACUMEN PHARMACEUTICALS INC (ABOS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001576885 · EDGAR filings · Updated 2026-06-17

ACUMEN PHARMACEUTICALS INC (ABOS) has reported institutional ownership of 63.7%, with 84 institutional managers holding positions valued at $108.5M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-06-17 — Insider transaction reported (Form 4)
• 2026-06-17 — Notice of proposed sale filed (Form 144)
• 2026-06-16 — Notice of proposed sale filed (Form 144)
• 2026-06-16 — Current report (8-K) filed
• 2026-06-15 — Notice of proposed sale filed (Form 144)
• 2026-06-10 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ACUMEN PHARMACEUTICALS INC has 84 institutional holders and institutional ownership of 63.7%.

Insider activity

Insiders reported 63 transactions (0 buys, 44 sells) across 15 reporting insiders, with a net reported value of −$536.1K.

Data flags from SEC filings

Related companies

Onkure Therapeutics Inc (OKUR) · LIFECORE BIOMEDICAL INC (LFCR) · SHOULDER INNOVATIONS INC (SI) · ARTIVA BIOTHERAPEUTICS INC (ARTV) · Kalaris Therapeutics Inc (KLRS) · PRELUDE THERAPEUTICS INC (PRLD)